X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2703) 2703
Publication (284) 284
Book Review (93) 93
Book Chapter (23) 23
Book / eBook (4) 4
Conference Proceeding (4) 4
Dissertation (2) 2
Magazine Article (2) 2
Data Set (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2192) 2192
female (2025) 2025
index medicus (1436) 1436
breast neoplasms - drug therapy (1422) 1422
breast cancer (1187) 1187
aromatase inhibitors (1149) 1149
oncology (1123) 1123
postmenopausal women (1007) 1007
aromatase inhibitors - adverse effects (906) 906
middle aged (883) 883
tamoxifen (863) 863
aromatase inhibitors - therapeutic use (800) 800
aged (707) 707
letrozole (512) 512
cancer (503) 503
antineoplastic agents, hormonal - therapeutic use (501) 501
postmenopause (498) 498
aromatase inhibitor (496) 496
anastrozole (495) 495
adult (494) 494
antineoplastic agents, hormonal - adverse effects (453) 453
breast neoplasms - pathology (443) 443
tamoxifen - therapeutic use (439) 439
estrogen (424) 424
endocrine therapy (418) 418
randomized-trial (418) 418
treatment outcome (414) 414
care and treatment (410) 410
triazoles - adverse effects (396) 396
nitriles - adverse effects (395) 395
nitriles - therapeutic use (390) 390
triazoles - therapeutic use (389) 389
aromatase (369) 369
women (352) 352
animals (345) 345
chemotherapy, adjuvant (341) 341
research (340) 340
male (310) 310
tamoxifen - adverse effects (309) 309
health aspects (304) 304
risk factors (295) 295
exemestane (281) 281
aromatase inhibitors - administration & dosage (280) 280
obstetrics & gynecology (277) 277
aged, 80 and over (270) 270
therapy (268) 268
drug therapy (257) 257
endocrinology & metabolism (250) 250
medicine & public health (250) 250
antineoplastic agents - therapeutic use (243) 243
chemotherapy (242) 242
antineoplastic agents - adverse effects (240) 240
pharmacology & pharmacy (224) 224
adjuvant treatment (213) 213
disease-free survival (200) 200
nitriles - administration & dosage (200) 200
triazoles - administration & dosage (199) 199
breast neoplasms - metabolism (190) 190
analysis (184) 184
randomized controlled trials as topic (184) 184
double-blind (181) 181
quality of life (181) 181
menopause (179) 179
osteoporosis (177) 177
clinical trials as topic (176) 176
trial (176) 176
article (171) 171
quality-of-life (171) 171
antineoplastic agents, hormonal - administration & dosage (167) 167
breast neoplasms - mortality (162) 162
breast-cancer (161) 161
aromatase inhibitors - pharmacology (159) 159
tamoxifen therapy (159) 159
womens health (157) 157
bone density - drug effects (156) 156
clinical trials (156) 156
androstadienes - therapeutic use (154) 154
prevention (152) 152
antineoplastic combined chemotherapy protocols - therapeutic use (150) 150
androstadienes - adverse effects (147) 147
neoplasms, hormone-dependent - drug therapy (146) 146
neoplasm staging (142) 142
hematology, oncology and palliative medicine (139) 139
bone-mineral density (137) 137
receptors, estrogen - metabolism (137) 137
breast neoplasms - surgery (136) 136
medicine, general & internal (136) 136
estradiol - blood (132) 132
review (132) 132
risk (132) 132
prospective studies (130) 130
time factors (130) 130
tamoxifen - administration & dosage (126) 126
estradiol (125) 125
cancer therapies (124) 124
drug administration schedule (124) 124
breast neoplasms - prevention & control (123) 123
hormone replacement therapy (119) 119
pregnancy (119) 119
double-blind method (118) 118
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2613) 2613
French (27) 27
Japanese (24) 24
German (18) 18
Chinese (9) 9
Italian (8) 8
Spanish (6) 6
Danish (4) 4
Hungarian (4) 4
Dutch (3) 3
Russian (3) 3
Swedish (3) 3
Czech (2) 2
Norwegian (2) 2
Slovak (2) 2
Polish (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2016, Volume 375, Issue 3, pp. 209 - 219
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 7, pp. 679 - 691
This large trial tested the effect of adding zoledronic acid to adjuvant endocrine treatment (goserelin plus tamoxifen or anastrozole) in premenopausal women... 
RECEIVING ADJUVANT LETROZOLE | MULTIPLE-MYELOMA | OVARIAN ABLATION | BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS | MEDICINE, GENERAL & INTERNAL | BONE LOSS | SOLID TUMORS | TAMOXIFEN | DELTA-T-CELLS | POSTMENOPAUSAL WOMEN | AUSTRIAN BREAST | Breast Neoplasms - surgery | Triazoles - adverse effects | Follow-Up Studies | Humans | Middle Aged | Receptors, Estrogen - analysis | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Drug Therapy, Combination | Goserelin - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Bone Density Conservation Agents - adverse effects | Premenopause | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Estrogen Antagonists - therapeutic use | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Zoledronic acid | Care and treatment | Usage | Breast cancer | Health aspects | Function tests (Medicine) | Chemotherapy | Acids | Womens health | Menopause | Colorectal cancer | Cytotoxicity | Radiation therapy | Cancer therapies | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 2013, Volume 24, Issue 2, pp. 398 - 405
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2128 - 2135
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 107 - 118
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4674 - 4682
Journal Article
Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 543 - 551
Palbociclib (Ibrance(A (R))) is an oral, reversible, selective, small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and CDK6 developed by Pfizer for... 
PD0332991 | PATHWAYS | TRIAL | DEPENDENT KINASE 4/6 | PD-0332991 | PHARMACOLOGY & PHARMACY | PROLIFERATION | TOXICOLOGY | SCHEDULE | INHIBITOR | PD 0332991 | PHASE-I | Piperazines - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drugs, Investigational - adverse effects | United States | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drugs, Investigational - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Drug Approval | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Neoplasm Recurrence, Local - pathology | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Pyridines - adverse effects | Drug Interactions | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Cyclin-Dependent Kinases - antagonists & inhibitors | Piperazines - pharmacokinetics | Aromatase Inhibitors - therapeutic use | United States Food and Drug Administration | Pyridines - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Neoplasm Recurrence, Local - prevention & control | Clinical Trials as Topic | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Breast Neoplasms - prevention & control | Protein Kinase Inhibitors - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Drugs, Investigational - administration & dosage | Neoplasm Staging | Nitriles - adverse effects | Nitriles - therapeutic use | Clinical trials | Care and treatment | Usage | Risk factors | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 5, pp. 436 - 446
Journal Article